TAS-119

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. Report Highlights Global KRAS Inhibitors Market Opportunity > USD 4 Billion By 2029 Global KRAS Drug Market Growth In 2022 > 200% Number Of Approved Drugs: 2 Drugs Approved Drug Global & Regional Sales Insight Approved Drugs Patent, Price & Dosage Analysis Regional Analysis: USA, UK, China Europe, Japan, South Korea Number Of Drugs In Clinical Trials: > 60 Drugs Insight On All Drugs In Clinical Trials By Phase, Company, Country, Indication & Patient Segment The advancement in the field of biology has led to the discovery of several oncogenes that play a critical role in cancer development and thus presenting researchers with opportunities to target them. KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitors. The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS. Researchers worldwide have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable. But after the approval of first-ever KRAS inhibitor, Lumakras (Sotorasib) developed by Amgen in 2021 for the treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer, the product market showed significant growth in terms of both commercial sale success and enhanced overall survival rates. Its sales grew more than twice in 2022 as compared to 2021 levels. The drug is the first ever targeted anti-cancer treatment drug against KRAS mutations. Furthermore, Qiagen also launched Therascreen KRAS RGQ PCR Kit after it received US regulatory approval as a companion diagnostic in aiding the diagnosis of non-small cell lung cancer. This was the first companion diagnostic kit to have received premarket approval from the US FDA. Nevertheless, additional progress has been made in the industry and FDA has further approved companion diagnosis kits. In December 2022 Agilent Resolution's ctDx FIRST was granted approval by the FDA as a companion diagnostic for patients with NSCLC. The ever-increasing cases of cancer and the ability of the tumor to develop new and frequent mutations signify an unmet need for advancement of novel therapies in the management and treatment of cancer. However, with discoveries like that of Kristen rat sarcoma viral oncogene homolog (KRAS), the future of cancer-targeted therapies is something to look forward to. It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer. With booming research and development strategies, pharmaceutical companies are rapidly moving forward and aiming for this oncogene. Recently, VITRAC Therapeutic has initiated a phase I clinical trial with AURKA Inhibitor VIC-1911 and Sotorasib a G12C inhibitor for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). This study of VIC-1911 as monotherapy and in combination with Sotorasib is being performed at Yale Cancer Centre. The preclinical studies have strongly supported the combinational use of both drugs. By using this multi-targeted approach, the study aims to provide a more effective therapeutic outcome for patients with KRAS G12C-mutated NSCLC. The market for KRAS-targeted drugs is poised with exponential growth with several factors determining its potential. The KRAS market is widely supported by the accelerating trend of preclinical and in vitro studies which has increased the number of patients that are seeking out treatment opportunities. The rising demand for this therapy has resulted in increasing acceptance of cancer management treatments. The market expects new medications to swiftly and rapidly enter the commercial sector. There are also factors that will be challenging the future potential of this market. With increased research and development activity, there also increases in the number of competitors in the market. Drug manufacturers need to develop medications that have innovation and creativity and the ability to show better outcomes than its opponents. Currently, Amgen is in the lead for KRAS targeted therapy market but with the incoming of more drugs in the future, some challenges are bound to be faced by the company if it wants to keep its position as the topmost stakeholder in the KRAS inhibitors drug market. For instance, on December 2022, the US FDA granted accelerated approval to Mirati Therapeutics' Adagrasib (Krazati) which is a RAS GTPase family inhibitor for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. This approval was based on KRYSTAL-1, a multicenter, open-label clinical trial and the indication was approved under accelerated approval based on the overall response rate and duration of response. Key Topics Covered: 1. Introduction to KRAS Inhibitors 2. Role of KRAS Inhibitors in Cancer Therapy 2.1 Lung Cancer 2.2 Pancreatic Cancer 2.3 Colorectal Cancer 2.4 Other Cancers 3. Lumakras - First Approved KRAS Inhibitor 3.1 Overview & Patent Insight 3.2 Dosage & Price Analysis 3.3 Sales Analysis 4. Krazati - Second Approved KRAS Inhibitor 4.1 Overview & Patent Insight 4.2 Dosage & Price Analysis 5. Global KRAS Inhibitor Market Outlook 5.1 Current Market Scenario 5.2 Future Market Opportunity 6. KRAS Inhibitor Market Regional Analysis 6.1 US 6.2 UK 6.3 China 6.4 Europe 6.5 Japan 6.6 South Korea 6.7 Canada 7. Global KRAS Inhibitors Clinical Pipeline Overview 7.1 By Country 7.2 By Phase 7.3 By Company 7.4 By Indication 7.5 By Patient Segment 8. Global KRAS Inhibitors Clinical Pipeline By Company, Indication & Phase 8.1 Research 8.2 Preclinical 8.3 Phase-I 8.4 Phase-I/II 8.5 Phase-II 8.6 Phase-III 9. Marketed KRAS Inhibitors Clinical Insight 9.1 Sotorasib - Amgen 9.2 Adagrasib - Mirati Therapeutics 10. Global KRAS Inhibitors Market Dynamics 10.1 Market Drivers & Opportunities for KRAS Inhibitors 10.2 Challenges for KRAS Inhibitors Market 11. Competitive Landscape 11.1 Array BioPharma 11.2 Applied Pharmaceutical Science 11.3 Amgen 11.4 AnBogen Therapeutics 11.5 Ascentage Pharma 11.6 AstraZeneca 11.7 BridgeBio Pharma 11.8 Boehringer Ingelheim 11.9 Erasca 11.10 Carmot Therapeutics 11.11 FogPharma 11.12 Frontier Medicines 11.13 Jacobio Pharmaceuticals 11.14 Jemincare 11.15 Jiangsu Hansoh Pharmaceutical 11.16 Jiangsu Hengrui Medicine Co. 11.17 Leidos Biomedical Research 11.18 Mirati Therapeutics 11.19 REVOLUTION Medicines 11.20 Roche 11.21 Shanghai Euregen Biopharma 11.22 Shanghai Yingli Pharmaceutical 11.23 Singh Biotechnology 11.24 Suzhou Genhouse Bio 11.25 Suzhou Zelgen Biopharmaceuticals For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Laura Wood | +353-1-481-1716 | [email protected] Logo: SOURCE Research and Markets

BOSTON--(BUSINESS WIRE)-- VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). The study is being performed at Yale Cancer Center with Sarah Goldberg, MD, MPH, as Principal Investigator (PI) and Study Chair; New York University Perlmutter Cancer Center, Vamsidhar Velcheti, MD, PI; University of California Davis Comprehensive Cancer Center, Jonathan Riess, MD, PI; University of Maryland Cancer Center, Katherine Scilla, MD, PI; Emory University Winship Cancer Center, Jennifer Carlisle, MD, PI. VIC-1911 is a novel, highly selective, and orally active small molecular inhibitor of aurora kinase A (AURKA). AURKA gene amplification/overexpression is reported in multiple tumors, including NSCLC. AURKA inhibition with VIC-1911 demonstrated monotherapy activity in KRAS G12C-mutant human NSCLC cells with intrinsic and acquired resistance to the G12C inhibitor sotorasib. In addition, the combination of VIC-1911 and sotorasib showed synergy in the same cell lines. Interestingly, NSCLC cells with intrinsic resistance to sotorasib showed the most profound synergistic effects with the combination of VIC-1911 and sotorasib. These findings suggested that 1) AURKA activation led to both intrinsic and acquired resistance to sotorasib in KRAS G12C-mutant NSCLC and 2) the combination of VIC-1911 and sotorasib may be a potential therapeutic approach for KRAS G12C-mutant patients with intrinsic and acquired resistance to sotorasib. In vivo data suggests both sotorasib and adagrasib are synergistic in combination with VIC-1911 in human KRAS G12C-mutant NSCLC cell line xenograft models. Additionally, in vivo studies demonstrated the synergy of VIC-1911 plus sotorasib compared with their respective monotherapies in KRAS G12C-mutant NSCLC xenograft models and a KRAS G12C-mutant PDX model. The combination of VIC-1911 plus sotorasib may be more active than sotorasib alone in KRAS G12C-mutant NSCLC that is naïve to G12C inhibitors. “We now have two approved KRAS G12C inhibitors, sotorasib and adagrasib, available to treat our patients with KRAS G12C-mutated NSCLC,” said Sarah Goldberg, MD, Study Chair. “Although response rates are considered good for patients naïve to KRAS G12C inhibitor therapy, more than 50% of patients have primary resistance and do not respond. In addition, many patients who do respond rapidly develop acquired resistance and relapse within months. With this new dual-targeted approach combining AURKA and KRAS G12C inhibitors, we hope to improve therapeutic outcomes for our patients with KRAS G12C-mutant NSCLC.” “VIC-1911 is a potent, selective AURKA inhibitor. Preclinical studies strongly support the combination of AURKA inhibition with VIC-1911 and KRAS G12C inhibitors in KRAS G12C-mutant NSCLC”, said Thomas Myers, MD, Chief Medical Officer. “By utilizing this multi-targeted approach, we hope to provide a more effective therapeutic outcome for patients with KRAS G12C-mutant NSCLC.“ About VITRAC Therapeutics, LLC: VITRAC is an integrated oncology research and development company with experience developing, managing, and optimizing global pharmaceutical drug development programs from late discovery, translational research, and clinical development through market authorization and post-marketing life-cycle management.